Douglas Miehm
Stock Analyst at RBC Capital
(2.17)
# 2,716
Out of 4,734 analysts
42
Total ratings
50%
Success rate
-6.94%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $141 → $143 | $111.89 | +27.80% | 5 | Dec 11, 2024 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $10 → $11 | $7.44 | +47.85% | 18 | Nov 1, 2024 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $20 → $23 | $17.36 | +32.49% | 10 | Oct 22, 2024 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $13 → $8 | $8.01 | -0.12% | 9 | Feb 16, 2024 |
Ligand Pharmaceuticals
Dec 11, 2024
Maintains: Outperform
Price Target: $141 → $143
Current: $111.89
Upside: +27.80%
Bausch Health Companies
Nov 1, 2024
Maintains: Sector Perform
Price Target: $10 → $11
Current: $7.44
Upside: +47.85%
Bausch + Lomb
Oct 22, 2024
Maintains: Outperform
Price Target: $20 → $23
Current: $17.36
Upside: +32.49%
Aurinia Pharmaceuticals
Feb 16, 2024
Maintains: Outperform
Price Target: $13 → $8
Current: $8.01
Upside: -0.12%